Adjunctive, Low-dose tPA in Primary PCI for STEMI

Phase 3 Completed 210 enrolled Population Health Research Institute Heart and Stroke Foundation of Canada · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Timeline

Start: 2018-04-01
Primary completion: 2024-09-17
Completion: 2025-02-12

Publications

Mehta SR, Pinilla-Echeverri N, Tiong D, Kovalova T, Sheth T, Natarajan MK, Sibbald M, Velianou JL, Welsh R, Har B, Jolly SS, Valettas N, Schwalm JD, Tsang M, Khatun R, Mian R, Cunningham J, Ly E, McCready T, Bainey KR. Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. J Am Coll Cardiol. 2026 Jan 27;87(3):238-248. doi: 10.1016/j.jacc.2025.10.008. Epub 2025 Oct 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alteplase	Protein / enzyme biologic	10 mg	Other
Subject	Alteplase	Protein / enzyme biologic	20 mg	Other

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Summary

Timeline

Publications

Drugs

Indications